Ecology and evolution as targets: The need for novel eco-evo drugs and strategies to fight antibiotic resistance

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 8, 2011, Pages 3649-3660

  Baquero, Fernando ^a   Coque, Teresa M ^a   De La Cruz, Fernando ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4,6 DIARYLPYRIDINE; 2' O METHYLOLIGORIBONUCLEOTIDE DERIVATIVE; AMIKACIN; ANTHRANILIC ACID; ANTIBIOTIC AGENT; BACTERIAL VACCINE; BETA LACTAM DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLODRONIC ACID; DEHYDROCREPENYNIC ACID; ETIDRONIC ACID; FIMBROLIDE DERIVATIVE; FURANONE DERIVATIVE; LECTIN INHIBITOR; LINOLEIC ACID; LINOLENIC ACID; MANOALIDE; N ACYLHOMOSERINE LACTONE; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PEPTIDE NUCLEIC ACID DERIVATIVE; PHOSPHORODIAMIDATE MORPHOLINO OLIGONUCLEOTIDE DERIVATIVE; PNEUMOCOCCUS VACCINE; PROBIOTIC AGENT; SALICYLIDENE ACYLHYDRAZIDE; SESTERTERPENE; TETRAMIC ACID DERIVATIVE; TETRONIC ACID DERIVATIVE; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL GENE; DISINFECTION; DRUG EFFICACY; DRUG MECHANISM; GENE SILENCING; HUMAN; INFECTION RISK; MICROBIAL COMMUNITY; MOLECULAR CLONING; MOLECULAR ECOLOGY; MOLECULAR EVOLUTION; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; SHORT SURVEY;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL PHYSIOLOGICAL PHENOMENA; CONJUGATION, GENETIC; DRUG RESISTANCE, BACTERIAL; EVOLUTION, MOLECULAR; GENES, MDR; INTERSPERSED REPETITIVE SEQUENCES; PUBLIC HEALTH; R FACTORS;

EID: 79960291267     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00013-11     Document Type: Short Survey

References (163)

1. Aiello, D., et al. 2010. Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion. Antimicrob. Agents Chemother. 54:1988-1999.
2. Amábile-Cuevas, C. F., and J. A. Heinemann. 2004. Shooting the messenger of antibiotic resistance: plasmid elimination as a potential counter-evolutionary tactic. Drug Discov. Today 9:465-467. (Pubitemid 38626076)
3. Askar, M., et al. 2011. Update on the ongoing outbreak of haemolytic uraemic syndrome due to Shiga toxin-producing Escherichia coli (STEC) serotype O104, Germany, May 2011. Euro Surveill. 16:19883.
4. Baquero, F. 2004. From pieces to patterns: evolutionary engineering in bacterial pathogens. Nat. Rev. Microbiol. 2:510-518.
5. Baquero, F. 2008. Modularization and evolvability in antibiotic resistance, p. 233-249. In F. Baquero, C. Nombela, G. Casell, and J. A. Gutierrez (ed.), Introduction to evolutionary biology of bacterial and fungal pathogens. ASM Press, Washington, DC.
6. Baquero, F. 2009. Environmental stress and evolvability in microbial systems. Clin. Microbiol. Infect. 15(Suppl. 1):5-10.
7. Baquero, F. 2009. Prediction: evolutionary trajectories and planet medicine. Microb. Biotechnol. 2:130-132.
8. Baquero, F., T. M. Coque, and R. Cantón. 2003. Antibiotics, complexity, and evolution. ASM News 69:547-552.
9. Baquero, F., J. L. Martínez, and R. Cantón. 2008. Antibiotics and antibiotic resistance in water environments. Curr. Opin. Biotechnol. 19:260-265.
10. Baquero, F., and M. C. Negri. 1997. Selective compartments for resistant microorganisms in antibiotic gradients. Bioessays 19:731-736.
11. Baquero, F., M. C. Negri, M. I. Morosini, and J. Blázquez. 1998. Antibioticselective environments. Clin. Infect. Dis. 27(Suppl. 1):S5-S11.
12. Barczak, A. K., and D. T. Hung. 2009. Productive steps toward an antimicrobial targeting virulence. Curr. Opin. Microbiol. 12:490-496.
13. Baron, C. 2010. Antivirulence drugs to target bacterial secretion systems. Curr. Opin. Microbiol. 13:100-105.
14. Benninger, M. S., and R. Manz. 2010. The impact of vaccination on rhinosinusitis and otitis media. Curr. Allergy Asthma Rep. 10:411-418.
15. Bjarnsholt, T., M. van Gennip, T. H. Jakobsen, L. D. Christensen, P. Ø. Jensen, and M. Givskov. 2010. In vitro screens for quorum sensing inhibitors and in vivo confirmation of their effect. Nat. Protoc. 5:282-293.
16. Blázquez, J., M. C. Negri, M. I. Morosini, J. M. Gómez-Gómez, and F. Baquero. 1998. A237T as a modulating mutation in naturally occurring extended-spectrum TEM-type beta-lactamases. Antimicrob. Agents Chemother. 42:1042-1044.
17. Bonhoeffer, S., M. Lipsitch, and B. R. Levin. 1997. Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl. Acad. Sci. U. S. A. 94:12106-12111.
18. Bonten, M. J., D. J. Austin, and M. Lipsitch. 2001. Understanding the spread of antibiotic resistant pathogens in hospitals: mathematical models as tools for control. Clin. Infect. Dis. 33:1739-1746.
19. Bootsma, M. C., O. Diekmann, and M. J. Bonten. 2006. Controlling methicillin-resistant Staphylococcus aureus: quantifying the effects of interventions and rapid diagnostic testing. Proc. Natl. Acad. Sci. U. S. A. 103:5620-5625.
20. Boucher, H. W., et al. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-2.
21. Brolund, A., M. Sundqvist, G. Kahlmeter, and M. Grape. 2010. Molecular characterisation of trimethoprim resistance in Escherichia coli and Klebsiella pneumoniae during a two year intervention on trimethoprim use. PLoS One 5:e9233.
22. Brown, S. P., S. A. West, S. P. Diggle, and A. S. Griffin. 2009. Social evolution in micro-organisms and a Trojan horse approach to medical intervention strategies. Philos. Trans. R. Soc. Lond. B 364:3157-3168.
23. Carattoli, A. 2009. Resistance plasmid families in Enterobacteriaceae. Antimicrob. Agents Chemother. 53:2227-2238.
24. Chakraborty, C. 2007. Potentiality of small interfering RNAs (siRNA) as recent therapeutic targets for gene-silencing. Curr. Drug Targets 8:469-482. (Pubitemid 46381297)
25. Cirz, R. T., et al. 2005. Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol. 3:e176.
26. Cirz, R. T., and F. E. Romesberg. 2007. Controlling mutation: intervening in evolution as a therapeutic strategy. Crit. Rev. Biochem. Mol. Biol. 42: 341-354.
27. Clatworthy, A. E., E. Pierson, and D. T. Hung. 2007. Targeting virulence: a new paradigm for antimicrobial therapy. Nat. Chem. Biol. 3:541-548.
28. Cornejo, O. E., D. E. Rozen, R. M. May, and B. R. Levin. 2009. Oscillations in continuous culture populations of Streptococcus pneumoniae: population dynamics and the evolution of clonal suicide. Proc. Biol. Sci. 276:999-1008.
29. Cottarel, G., and J. Wierzbowski. 2007. Combination drugs, an emerging option for antibacterial therapy. Trends Biotechnol. 25:547-555. (Pubitemid 350138177)
30. Couce, A., and J. Blázquez. 2009. Side effects of antibiotics on genetic variability. FEMS Microbiol. Rev. 33:531-538.
31. Courvalin, P. 2008. Predictable and unpredictable evolution of antibiotic resistance. J. Intern. Med. 264:4-16.
32. Czerkinsky, C., and J. Holmgren. 2010. Topical immunization strategies. Mucosal Immunol. 3:545-555.
33. Dandekar, T., and G. Dandekar. 2010. Pharmacogenomic strategies against microbial resistance: from bright to bleak to innovative. Pharmacogenomics 11:1193-1196.
34. Dantu, R., P. Kolan, and J. Cangussu. 2009. Network risk management using attacker profiling. Secur. Commun. Networks 2:83-96.
35. de Cristóbal, R. E., P. A. Vincent, and R. A. Salomón. 2008. A combination of sbmA and tolC mutations in Escherichia coli K-12 Tn10-carrying strains results in hypersusceptibility to tetracycline. J. Bacteriol. 190:1491-1494.
36. De Gelder, L., J. M. Ponciano, P. Joyce, and E. M. Top. 2007. Stability of a promiscuous plasmid in different hosts: no guarantee for a long-term relationship. Microbiology 153:452-463.
37. de la Cruz, F., L. S. Frost, R. J. Meyer, and E. L. Zechner. 2010. Conjugative DNA metabolism in Gram-negative bacteria. FEMS Microbiol. Rev. 34:18-40.
38. Denap, J. C., J. R. Thomas, D. J. Musk, and P. J. Hergenrother. 2004. Combating drug-resistant bacteria: small molecule mimics of plasmid incompatibility as antiplasmid compounds. J. Am. Chem. Soc. 126:15402-15404.
39. Deniaud, D., K. Julienne, and S. G. Gouin. 2011. Insights in the rational design of synthetic multivalent glycoconjugates as lectin ligands. Org. Biomol. Chem. 9:966-979.
40. Dethlefsen, L., M. McFall-Ngai, and D. A. Relman. 2007. An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature 449:811-818.
41. Diago-Navarro, E., L. Mora, R. H. Buckingham, R. Díaz-Orejas, and M. Lemonnier. 2009. Novel Escherichia coli RF1 mutants with decreased translation termination activity and increased sensitivity to the cytotoxic effect of the bacterial toxins Kid and Rel E. Mol. Microbiol. 71:66-78.
42. Didelot, X., and M. C. Maiden. 2010. Impact of recombination on bacterial evolution. Trends Microbiol. 18:315-322.
43. Dionisio, F., I. Matic, R. Miroslav, O. R. Rodrigues, and F. Taddei. 2002. Plasmids spread very fast in heterogeneous bacterial communities. Genetics 162:1525-1532. (Pubitemid 36114643)
44. Dörr, T., M. Vulić, and K. Lewis. 2010. Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biol. 8:e1000317.
45. Drew, R. H. 2009. Antimicrobial stewardship programs: how to start and steer a successful program. J. Manag. Care Pharm. 15(Suppl. 2):S18-S23.
46. Drlica, K., and X. Zhao. 2007. Mutant selection window hypothesis updated. Clin. Infect. Dis. 44:681-688.
47. Dwyer, D. J., M. A. Kohanski, and J. J. Collins. 2009. Role of reactive oxygen species in antibiotic action and resistance. Curr. Opin. Microbiol. 12:482-489.
48. Esposito, S., and M. Fiore. 2007. Community-acquired pneumonia: is it time to shorten the antibiotic treatment? Expert Rev. Anti Infect. Ther. 5:933-938.
49. Fajardo, A., et al. 2008. The neglected intrinsic resistome of bacterial pathogens. PLoS One 3:e1619.
50. Fennewald, M. A., and J. Capobianco. 1984. Isolation and analysis of inhibitors of transposon Tn3 site-specific recombination. J. Bacteriol. 159: 404-406. (Pubitemid 14084996)
51. Fernández-López, R., et al. 2005. Unsaturated fatty acids are inhibitors of bacterial conjugation. Microbiology 151:3517-3526. (Pubitemid 41632065)
52. File, T. M. 2004. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin. Infect. Dis. 39(Suppl. 3):S159-S164.
53. Fischbach, M. A., and C. T. Walsh. 2009. Antibiotics for emerging pathogens. Science 325:1089-1093.
54. Foster, K. R., and H. Grundmann. 2006. Do we need to put society first? The potential for tragedy in antimicrobial resistance. PLoS Med. 3:e29.
55. Frank, C. F., et al. 2011. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany - preliminary report. N. Engl. J. Med. [Epub ahead of print.] http://www.nejm.org/doi/pdf/10.1056/NEJMoa1106483.
56. Freitas, A. R., et al. 2011. Human and swine hosts share vancomycin-resistant Enterococcus faecium CC17 and CC5 and Enterococcus faecalis CC2 clonal clusters harboring Tn1546 on indistinguishable plasmids. J. Clin. Microbiol. 49:925-931.
57. Frost, L. S., R. Leplae, A. O. Summers, and A. Toussaint. 2005. Mobile genetic elements: the agents of open source evolution. Nat. Rev. Microbiol. 3:722-732.
58. Galán, J. C., et al. 2007. Mutation rate is reduced by increased dosage of mutL gene in Escherichia coli K-12. FEMS Microbiol. Lett. 275:263-269.
59. Garcillán-Barcia, M. P., and F. de la Cruz. 2008. Why is entry exclusion an essential feature of conjugative plasmids? Plasmid 60:1-18.
60. Ghosh, R. K., S. M. Ghosh, and S. Chawla. 2011. Recent advances in antiretroviral drugs. Expert Opin. Pharmacother. 212:31-46.
61. Gibson, J. L., et al. 2010. The sigma(E) stress response is required for stress-induced mutation and amplification in Escherichia coli. Mol. Microbiol. 77:415-430.
62. Girgis, H. S., A. K. Hottes, and S. Tavazoie. 2009. Genetic architecture of intrinsic antibiotic susceptibility. PLoS One 4:e5629.
63. Greenberg, D. E., et al. 2010. Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex. J. Infect. Dis. 201:1822-1830.
64. Guelfo, J. R., A. Rodríguez-Rojas, I. Matic, and J. Blázquez. 2010. A MATE-family efflux pump rescues the Escherichia coli 8-oxoguanine-repair- deficient mutator phenotype and protects against H2O2 killing. PLoS Genet. 6:e1000931.
65. Halary, S., J. W. Leigh, B. Cheaib, P. Lopez, and E. Bapteste. 2010. Network analyses structure genetic diversity in independent genetic worlds. Proc. Natl. Acad. Sci. U. S. A. 107:127-132.
66. Hawkey, P. M. 2008. Prevalence and clonality of extended-spectrum betalactamases in Asia. Clin. Microbiol. Infect. 14(Suppl. 1):159-165.
67. Hilleringmann, M., et al. 2006. Inhibitors of Helicobacter pylori ATPase Cagalpha block CagA transport and cag virulence. Microbiology 152:2919-2930. (Pubitemid 44542373)
68. Holmgren, J., and C. Czerkinsky. 2005. Mucosal immunity and vaccines. Nat. Med. 11(Suppl. 4):S45-S53.
69. Hughes, C. C., and W. Fenical. 2010. Antibacterials from the sea. Chemistry 16:12512-12525.
70. Keyser, P., M. Elofsson, S. Rosell, and H. Wolf-Watz. 2008. Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria. J. Intern. Med. 264:17-29.
71. Kidane, D., et al. 2009. Evidence for different pathways during horizontal gene transfer in competent Bacillus subtilis cells. PLoS Genet. 5:e1000630.
72. Kim, S. K., et al. 2009. Antibiotic resistance in bacteria: novel metalloenzyme inhibitors. Chem. Biol. Drug Des. 74:343-348.
73. Kim, H. U., et al. 2011. Integrative genome-scale metabolic analysis of Vibrio vulnificus for drug targeting and discovery. Mol. Syst. Biol. 7:460.
74. Knudsen, S., et al. 1995. Development and testing of improved suicide functions for biological containment of bacteria. Appl. Environ. Microbiol. 61:985-991.
75. Kohanski, M. A., M. A. DePristo, and J. J. Collins. 2010. Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol. Cell 37:311-320.
76. Kohanski, M. A., D. J. Dwyer, and J. J. Collins. 2010. How antibiotics kill bacteria: from targets to networks. Nat. Rev. Microbiol. 8:423-435.
77. Köhler, T., G. G. Perron, A. Buckling, and C. van Delden. 2010. Quorum sensing inhibition selects for virulence and cooperation in Pseudomonas aeruginosa. PLoS Pathog. 6:e1000883.
78. Lee, A. M., C. T. Ross, B. B. Zeng, and S. F. Singleton. 2005. A molecular target for suppression of the evolution of antibiotic resistance: inhibition of the Escherichia coli RecA protein by N(6)-(1-naphthyl)-ADP. J. Med. Chem. 48:5408-5411.
79. Lee, A. M., and S. F. Singleton. 2004. Inhibition of the Escherichia coli RecA protein: zinc(II), copper(II) and mercury(II) trap RecA as inactive aggregates. J. Inorg. Biochem. 98:1981-1986.
80. Lemonnier, M., L. Landraud, and E. Lemichez. 2007. Rho GTPase-activating bacterial toxins: from bacterial virulence regulation to eukaryotic cell biology. FEMS Microbiol. Rev. 31:515-534.
81. Lesic, B., et al. 2007. Inhibitors of pathogen intercellular signals as selective anti-infective compounds. Plos Pathog. 3:1229-1239. (Pubitemid 47510276)
82. Levin, B. R., and J. J. Bull. 2004. Population and evolutionary dynamics of phage therapy. Nat. Rev. Microbiol. 2:166-173.
83. Lewis, K. 2010. Persister cells. Annu. Rev. Microbiol. 64:357-372.
84. Lioy, V. S., O. Rey, D. Balsa, T. Pellicer, and J. C. Alonso. 2010. A toxinantitoxin module as a target for antimicrobial development. Plasmid 63:31-39.
85. López, E., and J. Blázquez. 2009. Effect of subinhibitory concentrations of antibiotics on intrachromosomal homologous recombination in Escherichia coli. Antimicrob. Agents Chemother. 53:3411-3415.
86. Lu, T. K., and J. J. Collins. 2009. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc. Natl. Acad. Sci. U. S. A. 106:4629-4634.
87. Luján, S. A., L. M. Guogas, H. Ragonese, S. W. Matson, and M. R. Redinbo. 2007. Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase. Proc. Natl. Acad. Sci. U. S. A. 104:12282-12287.
88. Maciá, M. D., et al. 2005. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob. Agents Chemother. 49:3382-3386.
89. Marraffini, L. A., and E. J. Sontheimer. 2008. CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science 322:1843-1845.
90. Martínez, J. L., and F. Baquero. 2002. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin. Microbiol. Rev. 15:647-679.
91. Mellbye, B. L., et al. 2010. Cationic phosphorodiamidate morpholino oligomers efficiently prevent growth of Escherichia coli in vitro and in vivo. J. Antimicrob. Chemother. 65:98-106.
92. Molina, L., C. Ramos, M. C. Ronchel, S. Molin, and J. L. Ramos. 1998. Construction of an efficient biologically contained Pseudomonas putida strain and its survival in outdoor assays. Appl. Environ. Microbiol. 64:2072-2078.
93. Molnár, J., et al. 1992. Antiplasmid activity: loss of bacterial resistance to antibiotics. APMIS Suppl. 30:24-31. (Pubitemid 23098809)
94. Morar, M., and G. D. Wright. 2010. The genomic enzymology of antibiotic resistance. Annu. Rev. Genet. 44:25-51.
95. Motter, A. E. 2010. Improved network performance via antagonism: from synthetic rescues to multi-drug combinations. Bioessays 32:236-245.
96. Moubareck, C., M. Lecso, E. Pinloche, M. J. Butel, and F. Doucet-Populaire. 2007. Inhibitory impact of bifidobacteria on the transfer of betalactam resistance among Enterobacteriaceae in the gnotobiotic mouse digestive tract. Appl. Environ. Microbiol. 73:855-860.
97. Munthali, M. T., K. N. Timmis, and E. E. Diaz. 1996. Use of colicin e3 for biological containment of microorganisms. Appl. Environ. Microbiol. 62:1805-1807.
98. Ni, B., Z. Du, Z. Guo, Y. Zhang, and R. Yang. 2008. Curing of four different plasmids in Yersinia pestis using plasmid incompatibility. Lett. Appl. Microbiol. 47:235-240.
99. Nogueira, T., et al. 2009. Horizontal gene transfer of the secretome drives the evolution of bacterial cooperation and virulence. Curr. Biol. 19:1683-1691.
100. Novais, A., et al. 2010. Evolutionary trajectories of beta-lactamase CTXM-1 cluster enzymes: predicting antibiotic resistance. PLoS Pathog. 6:e1000735.
101. Novotny, C., W. S. Knight, and C. C. Brinton, Jr. 1968. Inhibition of bacterial conjugation by ribonucleic acid and deoxyribonucleic acid male-specific bacteriophages. J. Bacteriol. 95:314-326.
102. Ochoa, T. J., et al. 2009. High frequency of antimicrobial drug resistance of diarrheagenic Escherichia coli in infants in Peru. Am. J. Trop. Med. Hyg. 81:296-301.
103. Ohlsen, K., G. Dandekar, R. Schwarz, and T. Dandekar. 2008. New trends in pharmacogenomic strategies against resistance development in microbial infections. Pharmacogenomics 9:1711-1723.
104. Ommen, G. S., and A. G. Motulsky. 2006. Ecogenetics: historical perspectives, p. 7-17. In L. G. Costa and D. L. Eaton (ed.), Gene-environment interactions. Fundamentals of ecogenetics. Wiley-Liss, Hoboken, NJ.
105. Padhye, S., P. Dandawate, M. Yusufi, A. Ahmad, and F. H. Sarkar. 9 November 2010. Perspectives on medicinal properties of plumbagin and its analogs. Med. Res. Rev. [Epub ahead of print]. doi:10.1002/med.20235
106. Pallen, M. J., and B. W. Wren. 2007. Bacterial pathogenomics. Nature 449:835-842.
107. Pan, Q., et al. 2005. Aptamers that preferentially bind type IVB pili and inhibit human monocytic-cell invasion by Salmonella enterica serovar typhi. Antimicrob. Agents Chemother. 49:4052-4060.
108. Paschos, A., et al. 2011. An in vivo high-throughput screening approach targeting the type IV secretion system component VirB8 identified inhibitors of Brucella abortus 2308 proliferation. Infect. Immun. 79:1033-1043.
109. Payne, D. J., M. N. Gwynn, D. J. Holmes, and D. L. Pompliano. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6:29-40.
110. Pérez-Mendoza, D., and F. de la Cruz. 2009. Escherichia coli genes affecting recipient ability in plasmid conjugation: are there any? BMC Genomics 10:71.
111. Petrova, V., S. Chitteni-Pattu, J. C. Drees, R. B. Inman, and M. M. Cox. 2009. An SOS inhibitor that binds to free RecA protein: the PsiB protein. Mol. Cell 36:121-130.
112. Prudhomme, M., L. Attaiech, G. Sánchez, B. Martin, and J. P. Claverys. 2006. Antibiotic stress induces genetic transformability in the human pathogen Streptococcus pneumoniae. Science 313:89-92.
113. Rankin, D. J., M. Bichsel, and A. Wagner. 2010. Mobile DNA can drive lineage extinction in prokaryotic populations. J. Evol. Biol. 23:2422-2431.
114. Rasko, D. A., et al. 2008. Targeting QseC signaling and virulence for antibiotic development. Science 321:1078-1080.
115. Rasko, D. A., and V. Sperandio. 2010. Anti-virulence strategies to combat bacteria-mediated disease. Nat. Rev. Drug Discov. 9:117-128.
116. Rogers, B. A., H. E. Sidjabat, and D. L. Paterson. 2011. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J. Antimicrob. Chemother. 66:1-14.
117. Ronchel, M. C., et al. 1998. Characterization of cell lysis in Pseudomonas putida induced upon expression of heterologous killing genes. Appl. Environ. Microbiol. 64:4904-4911.
118. Rowthorn, R. E., R. Laxminarayan, and C. A. Gilligan. 2009. Optimal control of epidemics in metapopulations. J. R. Soc. Interface 6:1135-1144.
119. Schwartz, G. H., D. Eiler, and M. Kern. 1965. Solubilization of the conjugation inhibitor from Escherichia coli cell wall. J. Bacteriol. 89:89-94.
120. Sexton, J. Z., et al. 2010. Novel inhibitors of E. coli RecA ATPase activity. Curr. Chem. Genomics 4:34-42.
121. Shen, Y., et al. 2010. Blueprint for antimicrobial hit discovery targeting metabolic networks. Proc. Natl. Acad. Sci. U. S. A. 107:1082-1087.
122. Shinners, E. N., and B. W. Catlin. 1988. Mutation in a locus linked to penB-nmp causes suppression of the Mtr phenotype of Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 32:971-977.
123. Singh, S. B., J. W. Phillips, and J. Wang. 2007. Highly sensitive target-based whole-cell antibacterial discovery strategy by antisense RNA silencing. Curr. Opin. Drug Discov. Dev. 10:160-166.
124. Skippington, E., and M. A. Ragan. 21 January 2011. Lateral genetic transfer and the construction of genetic exchange communities. FEMS Microbiol. Rev. [Epub ahead of print.] doi:10.1111/j.1574-6976.2010.00261.x
125. Smillie, C., M. P. Garcillán-Barcia, M. V. Francia, E. P. Rocha, and F. F. de la Cruz. 2010. Mobility of plasmids. Microbiol. Mol. Biol. Rev. 74:434-452.
126. Smith, D. L., S. A. Levin, and R. Laxminarayan. 2005. Strategic interactions in multi-institutional epidemics of antibiotic resistance. Proc. Natl. Acad. Sci. U. S. A. 102:3153-3158.
127. Smith, P. A., and F. E. Romesberg. 2007. Combating bacteria and drug resistance by inhibiting mechanisms of persistence and adaptation. Nat. Chem. Biol. 3:549-556.
128. Soler Bistué, A. J., et al. 2009. Inhibition of aac(6′)-Ib-mediated amikacin resistance by nuclease-resistant external guide sequences in bacteria. Proc. Natl. Acad. Sci. U. S. A. 106:13230-13235.
129. Sommer, M. O., G. Dantas, and G. M. Church. 2009. Functional characterization of the antibiotic resistance reservoir in the human microflora. Science 325:1128-1131.
130. Sorek, R., V. Kunin, and P. Hugenholtz. 2008. CRISPR - a widespread system that provides acquired resistance against phages in bacteria and archaea. Nat. Rev. Microbiol. 6:181-186.
131. Spengler, G., et al. 2003. Enhancement of plasmid curing by 9-aminoacridine and two phenothiazines in the presence of proton pump inhibitor 1-(2-benzoxazolyl)-3,3,3-trifluoro-2-propanone. Int. J. Antimicrob. Agents 22:223-227.
132. Spengler, G., et al. 2006. The mechanism of plasmid curing in bacteria. Curr. Drug Targets 7:823-841.
133. Standaert, B., N. Demarteau, S. Talbird, and J. Mauskopf. 2010. Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models? Vaccine 28(Suppl. 6):G30-G38.
134. Sufrin, J. R., S. Finckbeiner, and C. M. Oliver. 2009. Marine-derived metabolites of S-adenosylmethionine as templates for new anti-infectives. Mar. Drugs 7:401-434.
135. Sullivan, A., C. Edlund, and C. E. Nord. 2001. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect. Dis. 1:101-114.
136. Sultan, S. E. 2007. Development in context: the timely emergence of ecodevo. Trends Ecol. Evol. 22:575-582.
137. Sundqvist, M., et al. 2010. Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use. J. Antimicrob. Chemother. 65:350-360.
138. Suzuki, H., H. Yano, C. J. Brown, and E. M. Top. 2010. Predicting plasmid promiscuity based on genomic signature. J. Bacteriol. 192:6045-6055.
139. Tauber, A. I. 2010. Reframing developmental biology and building evolutionary theory's new synthesis. Perspect. Biol. Med. 53:257-270.
140. Thaller, M. C., et al. 2010. Tracking acquired antibiotic resistance in commensal bacteria of Galápagos land iguanas: no man, no resistance. PLoS One 5:e8989.
141. Thi, T. D., et al. 2011. Effect of recA inactivation on mutagenesis of Escherichia coli exposed to sublethal concentrations of antimicrobials. J. Antimicrob. Chemother. 66:531-538.
142. Thomas, J. R., J. C. DeNap, M. L. Wong, and P. J. Hergenrother. 2005. The relationship between aminoglycosides' RNA binding proclivity and their antiplasmid effect on an IncB plasmid. Biochemistry 44:6800-6808.
143. Torella, J. P., R. Chait, and R. Kishony. 2010. Optimal drug synergy in antimicrobial treatments. PLoS Comput. Biol. 6:e1000796.
144. Torres, B., S. Jaenecke, K. N. Timmis, J. L. García, and E. Díaz. 2000. A gene containment strategy based on a restriction- modification system. Environ. Microbiol. 2:555-563.
145. Trebichavsky, I., I. Splichal, R. Vojtech, and A. Splichalova. 2010. Modulation of natural immunity in the gut by Escherichia coli strain Nissle 1917. Nutr. Rev. 68:459-464.
146. Udekwu, K. I., N. Parrish, P. Ankomah, F. Baquero, and B. R. Levin. 2009. Functional relationship between bacterial cell density and the efficacy of antibiotics. J. Antimicrob. Chemother. 63:745-757.
147. van der Waaij, D., and C. E. Nord. 2000. Development and persistence of multi-resistance to antibiotics in bacteria: an analysis and a new approach to this urgent problem. Int. J. Antimicrob. Agents 16:191-197.
148. Wack, A., A. Seubert, and M. Hilleringmann. 2009. Novel vaccines. Vaccinations in the near and distant future. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 52:1083-1090. (In German.)
149. Wade, M. J., et al. 2010. Multilevel and kin selection in a connected world. Nature 463:E8-E10.
150. Wang, H., et al. 2011. Curing the plasmid pXO2 from Bacillus anthracis A16 using plasmid incompatibility. Curr. Microbiol. 62:703.
151. Warfield, K. L., R. G. Panchal, M. J. Aman, and S. Bavari. 2006. Antisense treatments for biothreat agents. Curr. Opin. Mol. Ther. 8:93-103.
152. West, S. A., S. Diggle, A. Buckling, A. Gardner, and A. S. Griffin. 2007. The social lives of microbes. Annu. Rev. Ecol. Evol. Syst. 38:53-77.
153. Wigle, T. J., et al. 2010. Screening for inhibitors of low-affinity epigenetic peptide-protein interactions: an AlphaScreen-based assay for antagonists of methyl-lysine binding proteins. J. Biomol. Screen. 15:62-71.
154. Wigle, T. J., et al. 2009. Inhibitors of RecA activity discovered by highthroughput screening: cell-permeable small molecules attenuate the SOS response in Escherichia coli. J. Biomol. Screen. 14:1092-1101.
155. Willems, R. W., W. P. Hanage, D. E. Bessen, and E. J. Feil. 2011. Population biology of Gram positive bacteria: high-risk clones for dissemination of antibiotic resistance. FEMS Microbiol. doi:10.1111/j.1574-6976.2011.00284.x.
156. Williams, J. J., and J. Hergenrother. 2008. Exposing plasmids as the Achilles' heel of drug-resistant bacteria. Curr. Opin. Chem. Biol. 12:389-399.
157. Wiuff, C., et al. 2005. Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations. Antimicrob. Agents Chemother. 49:1483-1494.
158. Woodford, N., J. F. Turton, and D. M. Livermore. 1 March 2011. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microb. Rev. [Epub ahead of print.] doi:10.1111/j.1574-6976.2011.00268.x.
159. Woodford, N., and D. W. Wareham on behalf of the UK Antibacterial Antisense Study Group. 2009. Tackling antibiotic resistance: a dose of common antisense? J. Antimicrob. Chemother. 63:225-229.
160. Wozniak, R. A., and M. K. Waldor. 2010. Integrative and conjugative elements: mosaic mobile genetic elements enabling dynamic lateral gene flow. Nat. Rev. Microbiol. 8:552-563.
161. Wright, G. D. 2009. Making sense of antisense in antibiotic drug discovery. Cell Host Microbe 6:197-198.
162. Wright, G. D. 2010. Q&A: Antibiotic resistance: where does it come from and what can we do about it? BMC Biol. 8:123.
163. Zaneveld, J., et al. 2008. Host-bacterial coevolution and the search for new drug targets. Curr. Opin. Chem. Biol. 12:109-114.